Gangliosides During Tumor Progression in Patients With Prostate Cancer
Abstract
The objective is to identify gangliosides associated with prostate cancer (Cap) and their ability to induce immune responses. Resorcinol-HCl and specific monoclonal antibodies were used on 2D-chromatograms, and to visualize on the cell surface with confocal-fluorescence microscopy. IgM against eight gangliosides from sera of patients with BPH, organ-confined and unconfined Cap, and age-matched healthy men were. analyzed by ELISA double-blinded and compared using ANOVA and Fisher's least significant difference methods. Endogenous IgM to gangliosides were measured in patients with confined CaP. CaP cells expressed GM1b, GM2, GD2, GD1a, and GM3. GM1a, GD1b and GT1b were undetectable. GM1b and GD1a were more prominent in AR-negative than in AR-positive cells. CaP patients differed from healthy and BPH patients in increased anti-GD2 and antiGD1a IgM and decreased anti-GD3. Other anti-ganglioside IgMs showed no difference among groups. The augmentation of anti-GD1a IgM in patients with organ-confined CaP but not in patients with uncoffined CaP or BPH or in healthy controls is striking (p < 0.025). The unique ganglioside profiles identify HH870 cell line a potential component of a polyvalent-vaccine for immunotherapy of CaP. Augmentation of anti-GD1a IgM in confined CaP may signify an earliest. immune response to eliminate GD1a from tumor microenvironment and circulation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2004
- Accession Number
- ADA429848
Entities
People
- Mepur H. Ravindranath